Use of MTX in the elderly and in patients with compromised renal function

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Morgaceva, O ^a   Furst, D E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Elderly; Methotrexate; Renal function

Indexed keywords

7 HYDROXYMETHOTREXATE; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; COLESTYRAMINE; CREATININE; DIAZEPAM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; HUMAN SERUM ALBUMIN; IBUPROFEN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; MESALAZINE; METHOTREXATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PETHIDINE; PHENYTOIN; PROBENECID; PROPRANOLOL; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SULFAPYRIDINE; WARFARIN;

AGED; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY SYSTEM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; KIDNEY; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER ENZYME BLOOD LEVEL; LOW DRUG DOSE; LUNG TOXICITY; MEGALOCYTOSIS; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PERITONEAL DIALYSIS; PHARMACODYNAMICS; POLYPHARMACY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANTIGEN PRESENTING CELL; BINDING AFFINITY; BLOOD FLOW VELOCITY; DRUG SYNTHESIS; ERYTHROCYTE SEDIMENTATION RATE; ESTIMATED GLOMERULAR FILTRATION RATE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GENE EXPRESSION PROFILING; HEART STROKE VOLUME; HYDROPHILICITY; HYDROXYLATION; KIDNEY TUBULE FUNCTION; LIPOPHILICITY; LIVER BLOOD FLOW; LIVER METABOLISM; LUNG DISEASE; OXYGEN CONSUMPTION; SKIN DISEASE; STOMACH ACID SECRETION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; HUMANS; KIDNEY; METHOTREXATE; MIDDLE AGED; RENAL INSUFFICIENCY; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650556032     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. DROSOS A: Methotrexate intolerance in elderly patients with rheumatoid arthritis what are the alternatives? Drugs Aging 2003;20:723-36.
2. BOEY O, VAN HOOLAND S, WOESTENBURG A, VAN DER Niepen P, VERBEELEN D: Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 2006;61:166-9.
3. SCHMUCKER DL, VESELL ES: Are the elderly underrepresented in clinical drug trials? Clin Pharmacol 1999;39:1103-8.
4. DURNAS C, LOI CM, CUSACK BJ: Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-89.
5. LE COUTEUR DG, HICKEY HM, HARVEY PJ, MCLEAN AJ: Oxidative injury reproduces age-related impairment of oxygen-dependent drug metabolism. Pharmacol Toxicol 1999;85:230-2.
6. ANANTHARAJU A, FELLER A, CHEDID A: Aging liver. A review. Gerontology 2002;48:343-53.
7. El DESOKY ES: Pharmacokinetic-Pharmacodynamic Crisis in the Elderly. Am J Ther 2007;14:488-98.
8. BEYTH RJ, SHORR RI: Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 2002;18:577-92.
9. CHUTKA DS, TAKAHASHI PY, HOEL RW: Inappropriate medications for elderly patients. Mayo Clin Proc 2004;79:122-39.
10. HILMERSN, GILLIAN SM, LE COUTEUR DG: Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 2005;1:151-6.
11. ABDELHAFIZ AH, BROWN S H M, BELLO A: Chronic kidney disease in older people: physiology, pathology, or both? Nephron Clin Pract 2010;116:19-24.
12. FAGNONI FF, VESCOVINI R, PASSERI G et al.: Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. Blood 2000;95:2860-8.
13. KHAN N, SHARIFF N, COBBOLD M et al.: Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169:1984-92.
14. RANGANATH VK, FURST DE: Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007;33:197-217.
15. WEBSTER SG, LEEMING JT: The appearance of the small bowel mucosa in old age. Ageing 1975;4:168-74.
16. HUSEBYE E, ENGEDAL K: The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol 1992;27:397-404.
17. BUSKIRK ER, HODGSON JL: Age and aerobic power: the rate of change in men and women. Fed Proc 1987;46:1824-9.
18. OGAWA T, SPINA RJ, MARTIN WH 3RD et al.: Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation 1992;86:494-503.
19. TURNHEIM K: When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843-53.
20. RITZ P: Chronic cellular dehydration in the aged patient. J Gerontol A Biol Sci Med Sci 2001;56: M349-52.
21. VALLNER JJ: Binding of drugs by albumin and plasma protein. J Pharm Sci 1977;66:447-65.
22. MANGONI AA, JACKSON SH: Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14.
23. GRANDISON MK, BOUDINOT FD: Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000;38:271-90.
24. Drug Information Online, 2010
25. BENET LZ, HOENER BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21.
26. FURST DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl. 2):20-25.
27. HANLON JT, PIEPER CF, HAJJAR ER et al.: Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006;61:511-5.
28. GUERRA PASARELLI MC, FILHO WJ: Adverse drug reactions in elderly patients: how to predict them? Einstein 2007;5:246-51.
29. PLEUVRYA BJ: Modes of drug elimination. Anaesthesia & Intensive Care Medicine. 2005;6:277-9.
30. ANANTHARAJU A, FELLER A, CHEDID A: A review. Gerontology 2002;48:343-53.
31. LUMHOLTZ B, KAMPMANN JJ, SIERSBAECK-NIELSEN K, HANSEN JM: Dose regimen of kanamycin and gentamycin. Acta Med Scand 1974;196:521-4.
32. KOFF RS, GARVEY AJ, BURNEY SW, BELL B: Absence of an age effect on sulfobromophtalein retention in healthy men. Gastroenterology 1973;65:300-2.
33. LE COUTEUR DG, MCLEAN AJ: The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359-73.
34. SCHMUCKER DL: Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001;18:837-51.
35. HUGHES SG: Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol 1998;46:531-533.
36. RAWLINS MD, JAMES OF, WILLLIAMS FM, WYNNE H, WOODHOUSE KW: Age and the metabolism of drugs. Q J Med 1987;64:545-7.
37. KINIRONS MT, OMAHONY MS: Drug metabolism and ageing. Br J Pharmacol 2004;57:540-4.
38. AYMANNS C, KELLER F, MAUS S, HARTMANN B, CZOCK D: Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010;5:314-27. Epub 2010 Jan 7.
39. MCLACHLAN MS: The ageing kidney. Lancet 1978;2:143-5
40. TURNHEIM K: Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-79.
41. DAVIES DF, SHOCK NW: Age changes in glomerular filtration rate, effective renal plasma flow and tubular secretory capacity in adult males. J Clin Invest 1950;29:496-507.
42. LINDEMAN RD, TOBIN J, SHOCK NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85.
43. HERMAN RA, VENG-PEDERSEN P, HOFFMAN J, KOEHNKE, FURST DE: Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989;78:165-71
44. AUVINET B, JARRIER I, LE LEVIER F et al.: Compared bioavailability of methotrexate administered orally or intramuscularly rheumatoid arthritis (in French) (letter). Presse Med 1992;21:822.
45. OGUEY D, KOLLIKER F, GERBER NJ et al.: Effect of food on the bioavailability of lowdose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:611-4.
46. NUERNBERG B, KOEHNKE R, SOLSKY M et al.: Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990;33:898-902.
47. ROSTAMI-HODJEGAN A, KROEMER HK, TUCKER GT: In vivo indices of enzyme activity. The effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 1999;9:277-86.
48. YUAN R, VENITZ J: Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther 2000;38:245-53.
49. PICHETTE V, LEBLOND FA: Drug metabolism in chronic renal failure. Curr Drug Metab 2003;4:91-103.
50. GREENBLATT DJ, DIVOLL M, HARMATZ JS, SHADER RI: Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980;215:86-91.
51. EFFROS RB, CAI Z, LINTON P: CD8 T cells and aging. Critical reviews in immunology 2003;23(no1-2): 45-64.
52. CHAN ES, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73. Epub 2002 Mar. 19.
53. GARDNER G, FURST DE: Disease-modifying antirheumatic drugs. Potential effects in older patients. Drugs Aging 1995;7:420-37.
54. FURST DE: Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis. J Rheumatol Suppl 1985;12(Suppl. 12): SI 1-4.
55. DERVIEUX T, FURST DE, LEIN DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
56. CHABNER BA, ALLEGRA CJ, CURT GA et al.: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985, 76:907-912.
57. MESSMANN R, ALLEGRA C: Antifolates: In: CHABNER B, LONGO D (Eds.): Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott Williams & Wilkins 2001: p. 139-84.
58. ALLEGRA CJ, DRAKE JC, JOLIVET J, CHABNER BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
59. CRONSTEIN BN: Molecular mechanism of methotrexate action in inflammation. Inflammation 1992;16:411-23.
60. KREMER J: The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994;21:1-5.
61. CRONSTEIN BN: Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
62. OLSEN NJ, CALLAHAN LF, PINCUS T: Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987;30:481-8.
63. BLEYER AW: The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 1978;41:36-51.
64. RICHEY DP, BENDER AD: Pharmacokinetic consequences of aging. Annu Rev Pharmacol Toxicol 1977;17:49-65.
65. JUNDT JW, BROWNE BA, FIOCCO GP, STEEL E AD, MOCK D: A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
66. KURNIK D, LOEBSTEIN R, FISHBEIN E et al.: Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57-63.
67. SHAPIRO WR, AUSMAN JI, RALL DP: Studies on the Chemotherapy of Experimental Brain Tumors: Evaluation of 1, 3-Bis (2-chloroethyl)-1nitrosourea, Cyclophosphamide, Mithramycin, and Methotrexate. Cancer Res 1970;30:2401-13.
68. CALVERT AH, BONDY PK, HARRAP KR: Some observations on the human pharmacology of methotrexate. Cancer Treat Rep 1977;61:1647-56.
69. SINNETT MJ, GROFF GB, RADDATZ DA et al.: Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1989;16:745-8.
70. JANKNEGT R, NUBE MJ, VAN DEN HOOGENBAND HM, OLDENHOF HG, STEENHOEK A, VREETB: Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. Pharm Weekbl Sci 1988;10:86-9.
71. BRESSOLLE F, BOLOGNA C, KINOWSKI JM et al.: Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997;24:1903-9.
72. BRESSOLLE F, BOLOGNA C, KINOWSKI JM, SAN Y J, COMBE B: Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998;57:110-3.
73. BALIS FM: Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 1986;11:223-35.
74. BASIN KS, ESCALANTE A, BEARDMORE TD: Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18:609-10.
75. CASSANO WF: Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 1989;11:481-2.
76. FURST DE, HERMAN RA, KOEHNKE R et al.: Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-6.
77. BOURKE RS, CHHEDA G, BREMER A, WATANABE O, TOWER DB: Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975;35:110-6.
78. SEIDEMAN P, MULLER-SUUR R: Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 1993;52:613-5. (Pubitemid 23246668)
79. FURST DE: The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997;36:1196-204.
80. RHEUMATOID ARTHRITIS CLINICAL TRIAL ARCHIVE GROUP: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995;22:218-23.
81. ELLMAN MH, GINSBERG D: Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis. Arthritis Rheum 1990;33:1060-1.
82. NAKAMURA M, SAKEMI T, NAGASAWA K: Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol 1999;26:1424-5.
83. BASILE C, MONTANARO A, SEMERARO A: Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transplant 2002;17:530-1.
84. CHATHAM WW, MORGAN SL, ALARCON G: Concise Communication. Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 2000;5:1185-6.
85. WALL SM, JOHANSEN MJ, MOLONY DA, DU BOSE TD JR, JAFFE N, MADDEN T: Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996;28:846-54.
86. AHMAD S, SHEN FH, BLEYER WA: Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978;138:1146-7.
87. HANDE KR, BALOW JE, DRAKE JC et al.: Methotrexate and hemodialysis [letter]. Ann Intern Med 1977;87:495-496.
88. BATTISONE MJ, WILLIAMS HI: Diseasemodifying antirheumatic drugs 1: methotrexate. In: HOCHBERG MC, SILMAN AJ, SMOLEN JS, WEINBLATT ME, WEISMANN MH (Eds.) Rheumatology. St. Louis, Missouri, US: Mosby 2004: p. 449-60.
89. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
90. TUGWELL P, BENNETT K, GENT M: Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987;107:358-66.
91. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
92. KREMER JM, LEE JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
93. FURST DE: Rational use of disease-modifying antirheumatic drugs. Drugs 1990;39:19-37.
94. FELSON DT, ANDERSON JJ, MEENAN RF: Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
95. WOLFE F, CATREY MA: The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991;18:973-7.
96. BOLOGNA C, VIU P, JORGENSEN C et al.: Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol 1996;35:453-7.
97. POOLE P, YEOMAN S, CAUGHEY D: Methotrexate in older patients with rheumatoid arthritis. Br J Rheumatol 1992;31:860.
98. GALIVAN J: Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980;17:105-10.
99. FATHI NH, MITROS F, HOFFMAN J et al.: Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002;29:2092-8.
100. FURST DE, KOEHNKE R, RIGGS C, LA BRECQUE R, MITROS FA: Perspective longitudinal study of liver biopsies in 40 RA patients on MTX followed for 6.5 years. Arthritis Rheum 1993;29(Suppl.): S19.
101. CASE JP: Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8:123-43.
102. HIRSHBERG B, MUSZKAT M, SCHLESINGER O et al.: Safety of Jow dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 2000;76:787-9.
103. NYFORS A: Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand (A) 1977;85:511-8. (Pubitemid 8149758)